RLMDRelmada Therapeutics, Inc.
$3.16+59% 1Y
$3.16
$1.9352 weeks$7.86
Price
+59%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality strong, a flag to check, the market against it.
P/En/a
Market value$331.5M
1 year+59%
5 years-88%
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 12, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 8, 2026Dated: September 8, 2026 RELMADA THERAPEUTICS, INC. By: /s/ Sergio Traversa Name: Sergio Traversa Title: Chief Executive Officer.Other event · Form 8-K
- Aug 6, 2026Relmada Therapeutics Reports Second Quarter.Earnings release · press release
- Jul 28, 2026Relmada Therapeutics Appoints Uro-Oncology Leader.Regulation FD disclosure · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.